ISM001-055 - AI-Discovered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Title

ISM001-055 - AI-Discovered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Content

Differentiating Biotech vs TechBio: The distinction between traditional Biotech and the emerging TechBio sector represents a shift in the strategic starting point of drug discovery. Traditional biotechnology is fundamentally biology-first; it typically begins with a specific therapeutic hypothesis derived from academic research around a simplified view of disease biology. This approach is often artisanal and asset-centric, relying on serial, human-intensive laboratory work to validate a specific biological target. Conversely, TechBio describes companies that utilize an engineering and data-first approach. Rather than focusing on a single asset, TechBio companies are platform-centric. They leverage massive, scaled data generation and artificial intelligence to create discovery engines capable of producing multiple assets across various indications. While traditional biotech aims to commercialize specific biological assets, TechBio aims to industrialize the discovery process itself, using high-performance computing to identify patterns in biological systems that are invisible to human researchers. Insilico Medicine exemplifies the TechBio evolution. Founded in 2014 by Alex Zhavoronkov at Johns Hopkins University, the company initially focused on using AI to analyze biological data for age-related applications. Recognizing the commercial necessity of validating their AI predictions, the company pivoted from being solely a software provider to a full-stack biotechnology enterprise. Insilico has expanded globally with offices in Massachusetts, New York, Hong Kong, Taipei, Montreal, Abu Dhabi, Shanghai and Yixing. Its proprietary Pharma.AI platform offers end-to-end services from new target identification to small molecule generation and clinical outcome prediction. Pharma.AI consists of Biology42, Chemistry42, Medicine42, and Science42, designed to operate across the entire drug discovery and development continuum. In 2016, Insilico published the first peer-reviewed concept describing the use of Generative Adversarial Networks for the design of novel molecules. In 2019, Insilico identified a molecule for the DDR1 kinase in just 21 days, validating the speed of AI in hit-to-lead generation. In 2021, Insilico nominated a preclinical candidate for Idiopathic Pulmonary Fibrosis (ISM001-055) in under 18 months, a significant reduction from the industry average of 4.5 years. In 2024, Insilico published Phase IIa results for ISM001-055 in Nature Biotechnology, providing the first comprehensive end-to-end validation of a generative AI drug in human patients.